

Anti-PDGFC / VEGFE Reference Antibody (Thrombogenics patent anti-PDGF-C)

Recombinant Antibody Catalog # APR11009

Specification

Anti-PDGFC / VEGFE Reference Antibody (Thrombogenics patent anti-PDGF-C) - Product Information

Application FC, E, FTA
Primary Accession Q9NRA1
Reactivity Human
Clonality Monoclonal
Isotype IgG1
Calculated MW 150 KDa

Anti-PDGFC / VEGFE Reference Antibody (Thrombogenics patent anti-PDGF-C) - Additional Information

Target/Specificity
PDGFC / VEGFE

Endotoxin

< 0.001EU/ μg, determined by LAL method.

Conjugation Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

Anti-PDGFC / VEGFE Reference Antibody (Thrombogenics patent anti-PDGF-C) - Protein Information

Name PDGFC

Synonyms SCDGF

Function

Growth factor that plays an essential role in the regulation of embryonic development, cell proliferation, cell migration, survival and chemotaxis. Potent mitogen and chemoattractant for cells of mesenchymal origin. Required for normal skeleton formation during embryonic development, especially for normal development of the craniofacial skeleton and for normal development of the palate. Required for normal skin morphogenesis during embryonic development. Plays an important role in wound healing, where it appears to be involved in three stages: inflammation, proliferation and remodeling. Plays an important role in angiogenesis and



blood vessel development. Involved in fibrotic processes, in which transformation of interstitial fibroblasts into myofibroblasts plus collagen deposition occurs. The CUB domain has mitogenic activity in coronary artery smooth muscle cells, suggesting a role beyond the maintenance of the latency of the PDGF domain. In the nucleus, PDGFC seems to have additional function.

Cellular Location

Cytoplasm, cytosol. Secreted. Nucleus. Cytoplasmic granule. Cell membrane. Note=Sumoylated form is predominant in the nucleus (PubMed:15247255). Stored in alpha granules in platelets (PubMed:15061151).

Tissue Location


Expressed in the fallopian tube, vascular smooth muscle cells in kidney, breast and colon and in visceral smooth muscle of the gastrointestinal tract. Highly expressed in retinal pigment epithelia. Expressed in medulloblastoma. In the kidney, constitutively expressed in parietal epithelial cells of Bowman's capsule, tubular epithelial cells and in arterial endothelial cells (at protein level) Highly expressed in the platelets, prostate, testis and uterus. Higher expression is observed in uterine leiomyomata. Weaker expression in the spleen, thymus, heart, pancreas, liver, ovary cells and small intestine, and negligible expression in the colon and peripheral blood leukocytes.

Anti-PDGFC / VEGFE Reference Antibody (Thrombogenics patent anti-PDGF-C) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture


Anti-PDGFC / VEGFE Reference Antibody (Thrombogenics patent anti-PDGF-C) - Images



Anti-PDGFC / VEGFE Reference Antibody (Thrombogenics patent anti-PDGF-C) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%







The purity of Anti-PDGFC / VEGFE Reference Antibody (Thrombogenics patent anti-PDGF-C) is more than 95% ,determined by SEC-HPLC.